Strike three: Bristol-Myers’ third I/O shot at glioblastoma misses as Opdivo flops yet again on key endpoint
Glioblastoma continues to defy about everything thrown at it.
Bristol-Myers Squibb put out word Thursday morning that its third Phase III assault on brain cancer using its star PD-1 Opdivo failed the first endpoint, with no significant improvement in progression-free survival for patients who face grim odds.
CheckMate-548 appears headed for a complete collapse, though overall survival is still being studied. Researchers had tried to see if the checkpoint therapy could outdo the standard of care by adding it to the standard — temozolomide and radiation therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.